Why India Is Keeping Innovator Companies Awake Unlike the US and Europe, where: Patents remain strong till 2031+ Biosimilar entry is tightly regulated Payors and insurers manage pricing and access India is different - and heres why companies like Novo Nordisk are cautious: 1
Clinical trials show the most significant appetite reduction happens between 1.0 mg and 1.7 mg weekly
In the SCALE Sleep Apnea RCT, liraglutide 3.0 mg was associated with a significant reduction of apnea-hypopnea index (AHI) compared to placebo (6.1 events per hour, 95% 11 to 1.2 events per hour) at 32 weeks in patients with moderate to severe OSA not on positive airway pressure 20
Off-Label Uses of Semaglutide 5.1 Semaglutide for PCOS and Metabolic Regulation 5.2 Non-Alcoholic Fatty Liver Disease (NAFLD/NASH) 5.3 Binge Eating Disorder and Appetite Dysregulation 5.4 Weight Loss in Non-Obese Individuals (Clinical Considerations) 5.5 Cardiovascular Disease Prevention Beyond Approved Scope 5.6 Adjunct in Metabolic Syndrome Management 5.7 Potential Neuroprotective and Anti-Inflammatory Roles (Emerging Research) 6
Appetite, digestion speed, and blood sugar regulation return to baseline, often causing hunger and cravings to reappear
Compounded medications carry their own separate risks (concentration variability, no FDA review)
.webp)
